Literature DB >> 14730035

Radiofrequency thermal ablation of abdominal tumors: lessons learned from complications.

Hyunchul Rhim1, Gerald D Dodd, Kedar N Chintapalli, Bradford J Wood, Damian E Dupuy, Julia L Hvizda, Patrick E Sewell, S Nahum Goldberg.   

Abstract

Radiofrequency (RF) thermal ablation has shown promise as a technique for treating inoperable solid tumors involving the liver, kidney, adrenal gland, and lung. However, like all other imaging-guided interventional procedures, RF ablation involves some element of risk. Varying degrees of complications can be expected, depending on factors such as the organ site and the aggressiveness of the procedure. General complications of RF ablation may be related to either imaging-guided electrode placement (eg, bleeding, infection, tumor seeding, pneumothorax) or thermal therapy (eg, nontarget thermal damage, grounding pad burns). Liver and renal-adrenal ablation may be associated with organ-specific complications. A fundamental understanding of RF ablation principles, along with adequate operator training and experience and familiarity with both thermal ablation and the broad spectrum of postablation complications, are necessary to maximize the safety and efficacy of this procedure. The standard of care for decreasing the morbidity of complications consists of prevention (including careful patient selection), early detection, and prompt, appropriate treatment. Copyright RSNA, 2004

Entities:  

Mesh:

Year:  2004        PMID: 14730035     DOI: 10.1148/rg.241025144

Source DB:  PubMed          Journal:  Radiographics        ISSN: 0271-5333            Impact factor:   5.333


  74 in total

Review 1.  Principles of and advances in percutaneous ablation.

Authors:  Muneeb Ahmed; Christopher L Brace; Fred T Lee; S Nahum Goldberg
Journal:  Radiology       Date:  2011-02       Impact factor: 11.105

2.  Long-term results of radiofrequency ablation for unresectable colorectal liver metastases: a potentially curative intervention.

Authors:  A A J M Van Tilborg; M R Meijerink; C Sietses; J H T M Van Waesberghe; M O Mackintosh; S Meijer; C Van Kuijk; P Van Den Tol
Journal:  Br J Radiol       Date:  2010-12-15       Impact factor: 3.039

3.  Thermo-sensitive hydrogel for preventing bowel injury in percutaneous renal radiofrequency ablation.

Authors:  Xin Wang; Xiaozhi Zhao; Tingsheng Lin; Hongqian Guo
Journal:  Int Urol Nephrol       Date:  2016-07-09       Impact factor: 2.370

4.  Cushing syndrome treated by radiofrequency ablation of adrenal gland adenoma.

Authors:  Naoko Nishi; Junji Tanaka; Akinobu Minagawa
Journal:  Jpn J Radiol       Date:  2012-01-25       Impact factor: 2.374

5.  A case of splenic abscess after radiofrequency ablation.

Authors:  Dimitris Zacharoulis; Emmanuel Katsogridakis; Constantinos Hatzitheofilou
Journal:  World J Gastroenterol       Date:  2006-07-14       Impact factor: 5.742

6.  Subdermal fluid for skin protection during superficial palliative thermal ablation.

Authors:  Deepak Sudheendra; Sergio Dromi; Bradford J Wood
Journal:  J Vasc Interv Radiol       Date:  2006-09       Impact factor: 3.464

7.  A tamponade leading to death after radiofrequency ablation of hepatocellular carcinoma.

Authors:  Ahmed Moumouh; Jérôme Hannequin; Carine Chagneau; Fatima Rayeh; Arnaud Jeanny; Alexandre Weber-Holtzscherer; Jean-Pierre Tasu
Journal:  Eur Radiol       Date:  2004-10-16       Impact factor: 5.315

8.  Numerical simulation of microwave ablation incorporating tissue contraction based on thermal dose.

Authors:  Dong Liu; Christopher L Brace
Journal:  Phys Med Biol       Date:  2017-02-02       Impact factor: 3.609

Review 9.  Diagnostic and therapeutic management of hepatocellular carcinoma.

Authors:  Francesco Bellissimo; Marilia Rita Pinzone; Bruno Cacopardo; Giuseppe Nunnari
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

Review 10.  Thermal Ablation of Renal Tumors: Indications, Techniques and Results.

Authors:  Marc Regier; Felix Chun
Journal:  Dtsch Arztebl Int       Date:  2015-06-12       Impact factor: 5.594

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.